Mithra Signs a License Agreement with Alvogen for its Estelle in Hong Kong and Taiwan
Shots:
- Mithra to get up front- sales milestones- royalties and recurring revenues based on Minimal Annual Quantities (MAQ) and will manufacture Estelle at its Contract Development and Manufacturing Organization facility in Belgium. Alvogen to get exclusive commercialization rights for Mithra’s Estelle in Hong Kong and Taiwan
- The agreement follows its previous licensing deals for Estelle in the US- EU- Russia- Canada- Brazil- Japan- South Korea- Middle East and South Africa with the focus of adding it to Alvogen’s women healthcare portfolio and develop footprints in Asia
- Estelle is a combined oral contraceptive (COC) of Estetrol (E4)15 mg & drospirenone (DRSP) 3 mg and has shown positive results including good bleeding profile- cycle control- and tolerability in P-III trial enrolling 3-725 women
Click here to read full press release/ article | Ref: Mithra | Image: PharmaWorld
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com